• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cumberland Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    3/19/25 5:07:29 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CPIX alert in real time by email
    cpix-20250319
    0001087294false00010872942025-03-192025-03-19

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

    March 19, 2025 (March 19, 2025)
    Date of Report (date of earliest event reported)

    CUMBERLAND PHARMACEUTICALS INC.
    (Exact name of registrant as specified in its charter)
    Tennessee
    001-33637
    62-1765329
    (State or other jurisdiction of incorporation or organization)
    (Commission File Number)
    (I.R.S. Employer Identification No.)
    1600 West End Avenue, Suite 1300 Nashville, Tennessee 37203
    (Address of Principal Executive Offices)
    (615) 255-0068
    Registrant's telephone number, including area code


    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, no par valueCPIXNASDAQ Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 8.01     Other Events
    On March 19, 2025, Cumberland Pharmaceuticals Inc. (“Cumberland”) announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a late-breaking presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas. The trial demonstrated significant cardiac benefits for patients with Duchenne muscular dystrophy (DMD), potentially addressing the leading cause of death in this devastating disease.
    A copy of the release is furnished as Exhibit 99.1.


    Exhibit No.Description
    99.1
    Press release dated March 19, 2025




    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
      Cumberland Pharmaceuticals Inc.
    Dated: March 19, 2025  By:/s/ John Hamm
      John Hamm
      Chief Financial Officer

    Get the next $CPIX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CPIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CPIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

     Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy NASHVILLE, Tenn., Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced strategic arrangements with RedHill Biopharma Ltd. (NASDAQ:RDHL), a specialty biopharmaceutical company, to jointly commercialize Talicia®. The FDA-approved oral capsule is indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer.

    10/20/25 9:05:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

    Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S. co-commercialization partnership designed to accelerate Talicia sales growth, leveraging Cumberland's expanded national sales promotion and marketing support, and deliver significant efficiencies through shared operational responsibility Transaction reinforces RedHill's financial position to advance its broader strategic objectives Patent protected through 2042 and with eight years QIDP market exclusivity, Talicia is:The #1 branded U.S. gastroenterologist-prescribed H. pylori therapy1 Listed first-line H. pylori therapy in American Colle

    10/20/25 9:00:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

    Premier Membership includes 4,350 U.S. Hospitals NASHVILLE, Tenn., Oct. 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, has added their potent antibiotic, Vibativ® (telavancin), to a national group purchasing agreement with Premier, Inc. Effective October 1, 2025 the product addition allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Vibativ® in both the 12-vial carton and the newly introduced 4-vial Starter Pak. With expanded access, Premier membe

    10/13/25 9:05:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Young Caroline increased direct ownership by 0.27% to 33,030 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    10/3/25 4:03:06 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jones James increased direct ownership by 0.58% to 44,192 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    10/3/25 4:02:16 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman and CEO Kazimi A J increased direct ownership by 0.00% to 5,700,284 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    10/3/25 4:01:46 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Young Caroline bought $398 worth of shares (121 units at $3.29), increasing direct ownership by 0.37% to 32,942 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:36:28 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jones James bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.60% to 43,938 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:35:26 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman and CEO Kazimi A J bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.00% to 5,700,030 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:34:18 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    SEC Filings

    View All

    Cumberland Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)

    10/21/25 9:25:32 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Cumberland Pharmaceuticals Inc.

    10-Q - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)

    8/8/25 5:03:12 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cumberland Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)

    8/5/25 5:05:48 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Leadership Updates

    Live Leadership Updates

    View All

    Sitryx appoints Adam Mostafa as Chief Financial Officer

    Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today. With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial

    9/8/25 7:00:00 AM ET
    $ABP
    $CPIX
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS

    NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors. Brown previously served for 10 years on the Board of directors of Brown-Forman Corporation, a large American wine and spirits company listed on the New York Stock Exchange. The brands in Brown-Forman's portfolio include Jack Daniel's and Woodford Reserve whiskeys, Benriach scotch, Herradura tequila and Finlandia vodka.  Brown is an attorney at Adams and Reese LLP, a

    7/19/22 9:25:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Financials

    Live finance-specific insights

    View All

    CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

     Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy NASHVILLE, Tenn., Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced strategic arrangements with RedHill Biopharma Ltd. (NASDAQ:RDHL), a specialty biopharmaceutical company, to jointly commercialize Talicia®. The FDA-approved oral capsule is indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer.

    10/20/25 9:05:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

    Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S. co-commercialization partnership designed to accelerate Talicia sales growth, leveraging Cumberland's expanded national sales promotion and marketing support, and deliver significant efficiencies through shared operational responsibility Transaction reinforces RedHill's financial position to advance its broader strategic objectives Patent protected through 2042 and with eight years QIDP market exclusivity, Talicia is:The #1 branded U.S. gastroenterologist-prescribed H. pylori therapy1 Listed first-line H. pylori therapy in American Colle

    10/20/25 9:00:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

    Premier Membership includes 4,350 U.S. Hospitals NASHVILLE, Tenn., Oct. 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, has added their potent antibiotic, Vibativ® (telavancin), to a national group purchasing agreement with Premier, Inc. Effective October 1, 2025 the product addition allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Vibativ® in both the 12-vial carton and the newly introduced 4-vial Starter Pak. With expanded access, Premier membe

    10/13/25 9:05:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

    SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)

    2/9/24 5:27:23 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

    SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)

    2/10/23 5:01:42 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

    SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)

    2/14/22 5:17:27 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care